
Melanoma
Latest News
Video Series

Latest Videos
Shorts




Podcasts
CME Content
More News

Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.

A Japanese study found favorable sensitivity and specificity for recurrence of melanoma based on presence of melanoma-specific markers in circulating tumor DNA.

mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma
The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

The tumor-infiltrating lymphocyte therapy has demonstrated potential for more convenient tissue collection and administration, an unmet need in advanced melanoma.

The FDA approved vusolimogene oderparepvec-wtpg plus nivolumab for PD-1–refractory advanced melanoma after a 10-3 advisory vote in favor of the oncolytic therapy.

Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.

FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
FDA advisers back RP1 plus nivolumab for anti–PD-1–refractory advanced melanoma, citing durable responses despite design concerns and awaiting confirmatory IGNYTE-3 data.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

During a live event, Sapna Patel, MD, and participants discussed second-line treatment selection for a patient with mucosal melanoma and considered how the limited available data shape that choice.

The clinicopathologic gene expression profile was granted the BDD status by the FDA for patients with T1b and T2a melanoma.

After 2 prior CRLs, the FDA accepted a resubmitted BLA as a complete class 1 response with a goal date of August 2, 2026 for the oncolytic therapy for melanoma.

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.











































